evipedia.ai
← Back

Jiaogulan for Health & Longevity

Evidence Review created on 08/25/2026 using AI4L / Opus 5

Also known as: Gynostemma pentaphyllum, Southern Ginseng, Five-Leaf Ginseng, Herb of Immortality, Miracle Grass, Amachazuru, Jiao Gu Lan, Sweet Tea Vine

Motivation

Jiaogulan (Gynostemma pentaphyllum) is a climbing vine of the cucumber family, native to the mountains of southern China and neighbouring parts of Asia, whose leaves are brewed as a mildly sweet tea. It attracts attention because it carries plant compounds that are chemically almost identical to those in ginseng, and because laboratory work ties its extracts to the cell’s main energy-sensing switch — the same switch that fasting and hard exercise engage.

In its home region the plant carries the folk name “herb of immortality”, attached to accounts of unusual old age among villagers in one mountainous province who drank the tea daily. Research has since moved well past that reputation: the leaf and its concentrated extracts have been tested in people for blood sugar handling, blood fats and body composition, and are now sold worldwide as loose tea, capsules and branded standardised extracts.

This review examines what the human evidence shows about jiaogulan — where controlled trials support an effect and how large it is, where the signal rests only on laboratory or animal work, what is known and unknown about its safety, and how it is dosed, sourced and monitored in practice.

Benefits - Risks - Protocol - Conclusion

High-level overviews, expert commentary and narrative reviews that frame jiaogulan’s chemistry, traditional use and clinical promise.

Note on priority sources: searches of foundmyfitness.com, peterattiamd.com, hubermanlab.com, chriskresser.com and lifespan.io returned no jiaogulan or Gynostemma pentaphyllum content at all. The herb falls outside the metabolic, supplement and longevity topics those five platforms have chosen to cover, so Life Extension is the only priority source represented above.

Grokipedia

  • Gynostemma pentaphyllum

    Dedicated encyclopedia entry covering the vine’s botany, distribution, saponin chemistry and traditional preparation as a sweet tea, useful for orientation on nomenclature and regional naming before reading the clinical literature.

Examine

  • Jiaogulan

    Independent grading of the human trial evidence, assigning a B grade to blood glucose and noting that only three trials with 105 participants underpin the entries. Includes a dosage section built from the tea trials.

ConsumerLab

Systematic Reviews

Systematic reviews and meta-analyses that pool the human trial data on jiaogulan, spanning blood lipids, blood sugar, fatty liver disease and the stress-hormone axis.

Trade-off coverage: pooled reviews exist for every claimed metabolic benefit, but no systematic review takes jiaogulan’s harms as its primary question. The risk side of the trade-off is therefore unrepresented in this literature, and safety evidence is confined to the adverse-event analysis embedded inside Dai et al., 2022.

Mechanism of Action

Jiaogulan’s activity is attributed to dammarane-type saponins called gypenosides; more than 300 are known, several structurally identical to the ginsenosides of Panax ginseng (Su et al., 2021).

The best-supported route is activation of AMPK. Active AMPK raises glucose uptake and fat burning while restraining mTOR (mechanistic target of rapamycin, the cellular growth-and-storage pathway) and the fat-synthesis enzymes downstream of SREBP (sterol regulatory element-binding protein, the master switch for making fat and cholesterol). The same reviews describe increased availability of the LDL receptor (the liver’s uptake port for low-density lipoprotein cholesterol) and altered bile-acid handling (Xie et al., 2024). Four weeks of leaf extract raised post-exercise AMPK activation in human muscle biopsies (Nayyar et al., 2023).

Two mechanistic accounts compete. The direct account holds that intact gypenosides act on the cell themselves, and adds inhibition of PTP1B (protein tyrosine phosphatase 1B, a brake on the insulin receptor) as the glucose-lowering step. The microbiome account holds that gypenosides are large sugar-bearing molecules that are barely absorbed, and that gut bacteria must strip those sugars to release aglycones such as damulin A and B, which are the true activators — making response partly a function of an individual’s gut flora (Huang et al., 2022).

Gypenosides are not a single drug. Oral absorption is low, elimination of the major saponins is rapid and largely hepatic and biliary, half-life figures come from animal work rather than human studies, and no selectivity or tissue-distribution profile has been established for the mixture as sold.

Historical Context & Evolution

Jiaogulan entered the written record not as a medicine but as food. It appears in the Ming-dynasty famine-relief herbal Jiuhuang Bencao (1406) as a plant to eat when crops failed. Only later did Chinese materia medica list it for cough, chronic bronchitis and hepatitis, and in Japan it circulated simply as amachazuru, sweet tea vine.

The turn toward health optimisation came from two directions in the 1970s. Japanese chemists Masahiro Nagai and Tsunematsu Takemoto found this cucumber-family vine contained saponins of ginseng’s dammarane class — some of them identical ginsenosides — hence the trade name southern ginseng. Independently, Chinese population surveys in mountainous Guizhou province recorded an unusual concentration of very old residents in districts where the leaf tea was a daily drink, and the “herb of immortality” label followed. A review of the genus traces both threads.

That Guizhou observation is worth stating precisely rather than dismissing. It was an uncontrolled geographic correlation, never designed to separate the tea from altitude, diet, physical labour or migration patterns, and it has not been retested with modern methods. It was not disproven; it was never adequately tested.

What changed since is the type of evidence, not the direction of the claim. Chinese lipid trials in the 1990s, Vietnamese and Swedish diabetes trials in the 2000s, and Korean and Australian body-composition trials in the 2010s replaced folk observation with randomised comparisons. The longevity claim itself remains untested in humans, and the current metabolic framing should not be read as the last word.

Expected Benefits

High 🟩 🟩 🟩

Improved Blood Sugar Control and Insulin Sensitivity

Jiaogulan lowers fasting glucose and improves how strongly tissues respond to insulin, chiefly through AMPK activation and by easing the brake PTP1B places on insulin signalling (Wang et al., 2026). Two independent trials run by Karolinska Institute investigators in drug-naive Vietnamese patients reproduced the effect using plain leaf tea rather than a proprietary extract, one showing improved insulin sensitivity on a somatostatin-insulin-glucose infusion test (Huyen et al., 2013). Trials run 4 to 12 weeks, are almost all Asian, and none has measured cardiovascular events.

Magnitude: Pooled mean difference −0.79 mmol/L (about −14 mg/dL) for fasting glucose (95% CI, the range within which the true effect most likely lies, −1.08 to −0.51) and −1.01 percentage points for HbA1c (glycated haemoglobin, roughly a three-month average of blood sugar; 95% CI −1.41 to −0.61) across eight studies in 584 patients.

Medium 🟩 🟩

Lower Triglycerides and Higher HDL Cholesterol ⚠️ Conflicted

Gypenosides suppress SREBP-driven fat synthesis and increase LDL-receptor availability, shifting the whole lipid panel. Two meta-analyses agree on lower triglycerides and higher HDL cholesterol (high-density lipoprotein, which carries cholesterol away from artery walls), and adding jiaogulan to statins or fibrates (standard cholesterol-lowering drugs) outperformed those drugs alone (Dai et al., 2022; Li et al., 2023). The HDL direction is contested: a genotype trial found HDL cholesterol fell after jiaogulan tea (Jeenduang et al., 2017). Pooling authors rated most evidence very low certainty, and red yeast rice beat jiaogulan head-to-head.

Magnitude: Added to lipid-lowering drugs, jiaogulan produced a further −0.65 mmol/L in triglycerides (95% CI −1.03 to −0.28), −0.57 mmol/L in LDL cholesterol (95% CI −1.07 to −0.08) and +0.15 mmol/L in HDL cholesterol (95% CI 0.11 to 0.20).

Reduced Body Fat and Waist Adiposity

Two placebo-controlled trials in overweight adults found fat loss without any deliberate change in diet or training. A heat-processed extract at 450 mg daily for 12 weeks reduced total abdominal fat area, body weight, fat mass and percent body fat (Park et al., 2014); a different commercial extract over 16 weeks reduced weight, body mass index and total fat mass (Rao et al., 2022). Both were funded by the ingredient manufacturers, a direct commercial interest in a positive result, and neither has been independently replicated.

Magnitude: In the 16-week trial, men taking the extract lost 109 g of visceral fat while placebo gained 12 g, and women lost 107 g of gynoid (hip and thigh) fat while placebo gained 95 g (both p < 0.05).

Improved Endurance Performance and Reduced Fatigue

Both human trials tie the effect to mitochondrial adaptation rather than stimulation. A four-week crossover in 16 untrained men improved 20 km time-trial performance alongside higher muscle oxygen flux and earlier AMPK activation after exercise (Nayyar et al., 2023). A 12-week trial in 100 adults raised maximal oxygen uptake and oxygen pulse (the oxygen delivered per heartbeat) and lowered perceived exertion (Ahn et al., 2023). Samples are small, the larger trial was run with a supplement manufacturer, and no trained athletes have been tested.

Magnitude: Maximal oxygen uptake and oxygen pulse were higher than placebo after 12 weeks (p = 0.007 and p = 0.047) and 20 km time-trial performance improved in the crossover trial; neither report gives a percentage change or effect size for the performance gain.

Low 🟩

Reduced Liver Fat and Liver Enzyme Levels

Over six months, adding jiaogulan to diet therapy in non-alcoholic fatty liver disease lowered body mass index, aspartate aminotransferase (a liver enzyme), insulin and insulin resistance beyond diet alone (Chou et al., 2006). A Cochrane review rated such herbal trials at high risk of bias.

Magnitude: Direction is consistently downward for liver enzymes and insulin resistance when jiaogulan is added to diet, and the 16-week body-composition trial also lowered alanine aminotransferase (Rao et al., 2022); no trial reports a liver-fat percentage change or a pooled effect size.

Lower Trait Anxiety Under Chronic Stress

Eight weeks of leaf extract at 200 mg twice daily reduced trait anxiety in 72 healthy adults under chronic stress, without changing cortisol, adrenocorticotropic hormone or heart-rate variability (Choi et al., 2019). A systematic review of botanicals and stress hormones judged this evidence unclear, and no trial has replicated it.

Magnitude: Trait anxiety score fell 16.8% more than placebo (p = 0.041); the total anxiety inventory score fell 17.8% but did not reach statistical significance (p = 0.067).

Improved Hair Density and Thickness

A 24-week trial in 100 adults reported large gains in hair elasticity, density and diameter against placebo, with no change in glossiness (Lee et al., 2025). The trial was run by the product manufacturer, is unreplicated, and used a drinkable formulation rather than capsules or tea.

Magnitude: Roughly three-fold increases in hair elasticity and density and a four-fold increase in hair diameter relative to placebo over 24 weeks.

Speculative 🟨

Anti-Cancer and Chemotherapy-Adjunct Activity

Gypenosides arrest the cell cycle, restore programmed cell death and blunt spread across many cancer cell lines and rodent tumour models (Li et al., 2016). No controlled human trial exists.

Neuroprotection and Cognitive Preservation

Cell and rodent work points to reduced brain inflammation and nerve-cell protection (Liang et al., 2024). The only randomised human test stopped early with ten participants and missed its endpoint (Lu et al., 2026).

Endothelial Function and Blood Pressure

Gypenosides trigger nitric-oxide release from arterial lining cells and relax coronary rings in the laboratory (Tanner et al., 1999). Human trials measuring blood pressure found no difference from placebo (Huyen et al., 2010).

Benefit-Modifying Factors

  • APOE and CETP genotype: In high-cholesterol tea drinkers, non-carriers of the APOE4 variant (a cholesterol-transport gene) had lower fasting glucose but also lower HDL cholesterol; CETP TaqIB B2 carriers (a cholesterol-shuttling gene) had lower total cholesterol. E4 carriers responded to neither (Jeenduang et al., 2017).

  • Gut microbiome composition: If deglycosylation by gut bacteria is required to release the active aglycones, individuals lacking the relevant bacterial enzymes may convert little of an ingested dose and respond weakly regardless of product quality.

  • Baseline glucose and lipid levels: Effects concentrate in people who start abnormal. Trials enrolled patients with type 2 diabetes or dyslipidaemia (abnormal blood fats); the meta-analysis found monotherapy and longer treatment gave larger glycaemic gains.

  • Sex: Fat loss appears to redistribute differently. In the 16-week body-composition trial (Rao et al., 2022), men lost visceral fat significantly while women lost gynoid fat; neither pattern appeared in the opposite sex.

  • Pre-existing metabolic disease: Metabolic syndrome, type 2 diabetes and fatty liver are the conditions in which benefit has been demonstrated. Lean, normoglycaemic people have only been studied for exercise performance and anxiety.

  • Age: All efficacy trials enrolled adults roughly 19 to 65. Nothing is known about response above 70, where age-related insulin resistance is common but polypharmacy and reduced kidney clearance also cluster.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Gastrointestinal Upset

Nausea, loose stools, increased bowel movements and abdominal discomfort are the most frequently reported adverse events, plausibly reflecting the detergent-like action of saponins on the gut lining. The systematic review of 22 trials found jiaogulan produced fewer adverse events than statin, fibrate and fish-oil comparators (Dai et al., 2022), and rats given up to 750 mg/kg daily for six months showed no dose-related toxicity (Attawish et al., 2004). Symptoms are mild, dose-related and reverse on stopping.

Magnitude: In the 16-week placebo-controlled trial (Rao et al., 2022), 5 of 60 people taking jiaogulan reported an adverse event (diarrhoea, insomnia, dizziness, nausea, dry throat) versus 2 of 57 on placebo — roughly 8% against 4%.

Medium 🟥 🟥

Additive Blood-Sugar Lowering

Because jiaogulan lowers fasting glucose partly through insulin-independent AMPK activation, stacking it on sulfonylureas (insulin-releasing diabetes tablets), insulin or a maximal metformin dose can drive glucose below the intended target. No hypoglycaemic episode was recorded in the controlled trials, which enrolled drug-naive or diet-treated patients (Huyen et al., 2010); the concern is extrapolated from the size of the glucose effect rather than observed. Risk concentrates in people already titrated to target.

Magnitude: The glucose-lowering effect available to stack on existing therapy is a pooled −0.79 mmol/L in fasting glucose and −1.01 percentage points in HbA1c.

Low 🟥

Platelet Suppression and Bleeding Risk ⚠️ Conflicted

A 2025 case report describes severe thrombocytopenia (a dangerously low platelet count) after three months of daily use, fully reversed on withdrawal (Ding et al., 2025). The direction is contested: a 1985 study isolated a platelet-aggregation-promoting factor (Takagi et al., 1985), while gypenosides release nitric oxide, which inhibits aggregation.

Magnitude: In the single reported case, platelets fell to 6 × 10⁹/L against a normal range of roughly 150–450 × 10⁹/L, and rebounded to 156 × 10⁹/L after the herb was stopped.

Mild Red-Cell and Haemoglobin Decline

The 12-week obesity trial recorded small falls in red blood cells, haemoglobin and haematocrit alongside platelets, all staying inside normal limits (Park et al., 2014). Anyone already anaemic starts closer to the threshold where a further fall matters.

Magnitude: Direction is downward for red blood cells, haemoglobin and haematocrit over 12 weeks of extract, with every value staying inside the normal reference range; the trial report gives no outcome figure for the size of the fall.

Product Variability, Adulteration and Contamination

Gypenoside content varies with species, plant part, growing region and processing: a standardised research extract carried only 6% gypenosides (Chiranthanut et al., 2013), and heat-processed products differ chemically from raw leaf. Substitution with related Gynostemma species and heavy-metal residues are recognised botanical supply-chain concerns.

Magnitude: Not quantified in available studies. No published survey has tested marketed jiaogulan products for gypenoside content, species identity or contaminants, so the frequency of substandard product is unmeasured.

Speculative 🟨

Symptomatic Low Blood Pressure with Antihypertensives

Gypenosides release nitric oxide and relax arteries in laboratory preparations, which could add to blood-pressure medication. Human trials measuring blood pressure found no change (Huyen et al., 2010), so this rests on mechanism alone.

Immune Activation in Autoimmune Disease or After Transplant

Mouse work shows jiaogulan extract raises antibody and cytokine production (Huang et al., 2007). Whether that could destabilise autoimmune disease or graft tolerance has never been tested in people; the concern is mechanistic.

Exposure in Pregnancy and Lactation

No reproductive toxicity study and no human pregnancy data exist for jiaogulan, and traditional Chinese practice discourages its use in pregnancy. Absence of evidence, not evidence of harm, drives this classification.

Risk-Modifying Factors

  • Genetic polymorphisms: No pharmacogenetic variant has been validated for jiaogulan safety. Because the gypenoside mixture has no established metabolising enzyme, variants in CYP enzymes (the liver’s main drug-processing family) cannot currently be used to predict risk.

  • Baseline platelet count and clotting status: A starting platelet count in the low-normal band, or an existing bleeding tendency, magnifies the consequence of the reported thrombocytopenia signal and of any effect on platelet aggregation.

  • Sex-based differences: No sex difference in adverse events has been reported. Trial adverse-event tables were not analysed by sex, so a difference could exist and remain undetected.

  • Pre-existing conditions: Treated diabetes, bleeding disorders, planned surgery, autoimmune disease, organ transplantation and advanced liver disease each convert a theoretical pharmacological effect into a clinically meaningful one.

  • Age: Older adults carry more polypharmacy, more antiplatelet and anticoagulant use, and thinner physiological reserve for a drop in platelets or glucose, while being entirely unrepresented in the trial populations.

Key Interactions & Contraindications

  • Sulfonylureas (glimepiride, gliclazide, glipizide) and insulin: Caution. Additive glucose lowering can cause hypoglycaemia. Fingerstick glucose over the first four weeks, with a drug dose reduction if readings trend low, is the practical mitigation.

  • Metformin: Caution. Both act partly through AMPK, so the metabolic effect may be additive rather than redundant. Clinically mild; a glucose check after four weeks of combined use is the usual precaution.

  • Warfarin and direct oral anticoagulants (apixaban, rivaroxaban, edoxaban): Caution. A theoretical additive bleeding risk from platelet effects. A platelet count before starting and again at four weeks, plus international normalised ratio testing on warfarin, is the usual precaution.

  • Antiplatelet drugs (aspirin, clopidogrel, ticagrelor): Caution. Same theoretical bleeding concern. Separate timing does not help; monitoring platelet count and bruising is the practical mitigation.

  • Immunosuppressants (tacrolimus, ciclosporin, mycophenolate, azathioprine): Absolute contraindication in transplant recipients. Animal evidence of immune stimulation raises a plausible risk of graft rejection that cannot be monitored around.

  • Antihypertensives (amlodipine, lisinopril, losartan): Monitor. Possible additive vasodilation causing dizziness on standing. Seated and standing blood pressure at two and four weeks detects it.

  • Over-the-counter analgesics (ibuprofen, naproxen, high-dose aspirin): Caution. These already impair platelet function and irritate the gut, compounding both the bleeding and the gastrointestinal side of jiaogulan.

  • Glucose-lowering supplements (berberine, alpha-lipoic acid, chromium picolinate, cinnamon extract, bitter melon): Caution, additive hypoglycaemia. These have the same directional effect as jiaogulan and are commonly stacked without anyone tracking the total.

  • Bleeding-risk supplements (fish oil, ginkgo, garlic extract, nattokinase, high-dose vitamin E): Caution. Additive antiplatelet effect. Pausing jiaogulan rather than the others is the usual response if bruising or gum bleeding appears.

  • Panax ginseng and other dammarane-saponin botanicals: Monitor. Overlapping saponin chemistry means combining them raises total saponin exposure without adding a distinct mechanism, increasing gastrointestinal complaints.

  • Prolonged fasting, very-low-carbohydrate diets and high-volume endurance training: Monitor. Each independently activates AMPK and lowers glucose; combined with jiaogulan the total effect can exceed what any single input would predict.

Populations who should avoid Jiaogulan:

  • Pregnant or breastfeeding women, at any dose, given the complete absence of reproductive safety data
  • Solid-organ transplant recipients on immunosuppression, at any time post-transplant
  • Anyone with a platelet count below 150 × 10⁹/L, or with a diagnosed bleeding disorder such as von Willebrand disease or immune thrombocytopenia
  • Anyone within 14 days of planned surgery or an invasive procedure with bleeding risk
  • People with active autoimmune disease in a flare, particularly systemic lupus erythematosus or rheumatoid arthritis on biologic therapy
  • Children and adolescents under 18, who have never been enrolled in any trial

Risk Mitigation Strategies

  • Half dose for the first two weeks: A half dose — 3 g of dried leaf as tea, or 225 mg of standardised extract — precedes the full dose. This limits the gastrointestinal upset that is the most common adverse event.

  • Dosing with food: Dosing alongside a meal blunts the saponin irritation of the gut lining that causes nausea and loose stools, and slows the glucose effect in anyone on diabetes medication.

  • Baseline and four-week platelet count: A complete blood count before starting and at four weeks detects the reported thrombocytopenia signal early, while it is still fully reversible on withdrawal.

  • Fingerstick glucose monitoring for treated diabetes: Daily fasting and pre-dinner readings over four weeks, in people on sulfonylureas or insulin, catch additive lowering before it becomes symptomatic hypoglycaemia.

  • Fourteen-day washout before surgery or dental extraction: This clears any platelet-aggregation effect well beyond the rapid elimination of the saponins and prevents avoidable perioperative bleeding.

  • Species-verified, gypenoside-standardised product: Requiring a stated gypenoside percentage and botanical identity testing mitigates the substitution and contamination risk that unstandardised leaf powder carries.

  • Reassessment at 12 weeks against a measured endpoint: If fasting glucose, triglycerides or body composition have not moved, discontinuing avoids indefinite exposure to a compound with no long-term human safety record.

Therapeutic Protocol

  • Traditional tea approach: 6 g of dried leaf daily, steeped as tea, is the dose used in both Karolinska-run diabetes trials and remains the only regimen validated on plain leaf rather than a proprietary extract.

  • Standardised extract approach: 450 mg daily of heat-processed extract is the dose used in the Korean obesity trial and in the exercise crossover, and is the format most commercial capsules follow.

  • Competing approaches presented side by side: Neither is the default. Tea has the diabetes evidence and lower cost; heat-processed extract has the body-composition and performance evidence and far more consistent dosing.

  • Popularising sources: The tea protocol traces to Karolinska Institute investigators working with Hanoi Medical University; the heat-processed extract route traces to Chonbuk National University Hospital’s Clinical Trial Center for Functional Foods and to retailers such as Life Extension.

  • Best time of day: Morning or pre-exercise is the common choice, matching the AMPK and glucose-uptake mechanism to the fed, active part of the day. One trial (Rao et al., 2022) reported insomnia as an adverse event, favouring earlier dosing.

  • Half-life and dosing frequency: Human half-life data are not established; elimination of the major saponins appears rapid, which is why trials that used extract split the dose morning and evening rather than giving it once.

  • Single versus split dosing: The anxiety trial used 200 mg twice daily, and the obesity and body-composition trials split 450 mg into 225 mg before breakfast and dinner. Splitting reduces gastrointestinal complaints and matches the regimens the extract trials used.

  • Genetic polymorphisms influencing dose: APOE4 carriers showed no cholesterol or glucose response to tea in the genotype study (Jeenduang et al., 2017), so a longer trial period or a different endpoint is reasonable before judging response in that group.

  • Sex-based differences in response: No dose adjustment is established. The observed difference is in where fat is lost rather than how much, so protocol choice need not differ by sex.

  • Age considerations: No trial enrolled anyone over 65 as a defined group. For adults in their late sixties and beyond, starting at the tea dose and monitoring platelets and glucose more closely is the conservative course.

  • Baseline biomarkers influencing response: Elevated fasting glucose, HbA1c or triglycerides predict a measurable response; normal values predict little. Measuring before starting is what makes a 12-week reassessment meaningful.

  • Pre-existing conditions influencing response: Type 2 diabetes, metabolic syndrome and fatty liver are the states in which effects were demonstrated. In their absence, the realistic expectation is the small performance and fatigue effect only.

Discontinuation & Cycling

  • Intended duration: Jiaogulan is used both as a daily long-term tea in its home region and as a defined 12 to 24 week course in trials. No trial ran beyond 24 weeks, so indefinite use is untested.

  • Withdrawal effects: None reported. The trials record no rebound in glucose, lipids or anxiety after treatment stopped, and the case of thrombocytopenia resolved rather than worsened on withdrawal.

  • Tapering: Not required. There is no receptor downregulation or dependency mechanism, and the exercise crossover trial (Nayyar et al., 2023) stopped supplementation abruptly with a four-week washout and no adverse consequence.

  • Cycling for continued efficacy: No tolerance has been documented, so cycling is not needed to preserve effect. The meta-analysis found longer continuous treatment produced larger glycaemic gains than short courses.

  • Practical reason to cycle anyway: Scheduled breaks every 12 weeks create natural reassessment points for platelets, glucose and lipids, which substitutes for the long-term safety data that does not yet exist.

Sourcing and Quality

  • Species identity: Product labelled Gynostemma pentaphyllum with botanical verification is the reliable choice. The genus contains several related species with different saponin profiles, and leaf powder is easy to substitute undetectably.

  • Gypenoside standardisation: A stated gypenoside percentage is the key label marker. The extract used in toxicity testing carried 6% (Chiranthanut et al., 2013); commercial extracts range widely, and an unstated figure means the dose in the capsule is unknown.

  • Raw leaf versus heat-processed extract: Heat processing converts gypenosides into damulin A and B, the aglycones credited with AMPK activation. Body-composition and performance trials used heat-processed material; tea trials did not.

  • Third-party testing: Certificates of analysis for heavy metals, pesticide residues and microbial counts are the relevant documentation. Jiaogulan is often wild-harvested or grown in regions where soil cadmium and lead are documented concerns.

  • Named research ingredients: Actiponin, the heat-processed extract used in the Korean obesity trial, and ActivAMP, used in the Australian body-composition trial, are the two forms with published human trial data behind them.

  • Retailers with a stake in the conclusion: Life Extension both publishes favourable jiaogulan content and sells the supplement, which makes its sourcing guidance commercially interested rather than independent.

  • Form and freshness: Fresh loose leaf is green rather than brown and tastes sweet then bitter. A manufacture date on capsules matters, as saponin content declines with prolonged warm storage.

Practical Considerations

  • Time to effect: Glucose and insulin sensitivity shift within 4 to 12 weeks; lipid changes were measured at 8 to 12 weeks; body-composition change took 12 to 16 weeks. Nothing meaningful is measurable before four weeks.

  • Common pitfall — expecting a stimulant: The fatigue and performance effect comes from mitochondrial adaptation, not stimulation. People who judge it by acute feel within days conclude wrongly that it does nothing.

  • Common pitfall — unstandardised leaf at extract doses: 450 mg of raw leaf powder is not equivalent to 450 mg of heat-processed extract. Conflating the two produces a dose far below anything tested.

  • Common pitfall — silent stacking: Jiaogulan is often added on top of berberine, cinnamon and fish oil without recalculating total glucose and bleeding effect. Each is individually modest; the sum is not.

  • Regulatory status: In the United States it is a dietary supplement, not an approved drug, so no efficacy claim is federally reviewed. It has traditional food status in China and is sold as a food-grade tea across East Asia.

  • Cost and accessibility: Inexpensive and widely available — leaf tea costs a few cents per daily dose and standardised extract a few dollars per month. Neither cost nor access is a meaningful barrier.

  • Payer incentive and research funding: No insurer or national health system reimburses jiaogulan, while the drugs it is compared against are cheap reimbursed generics. Neither payers nor drug makers have a financial reason to fund confirmatory trials, which leaves supplement manufacturers as the main sponsors.

Interaction with Foundational Habits

  • Sleep: Direct and mixed. Insomnia appeared as an adverse event in the 16-week body-composition trial (Rao et al., 2022), while the anxiety trial found lower trait anxiety without sleep complaints. The mechanism is unclear. Practical approach: the full dose falls before mid-afternoon, with sleep quality reassessed after two weeks rather than either direction assumed.

  • Nutrition: Potentiating with carbohydrate-containing meals, since the AMPK-mediated increase in glucose uptake acts on post-meal glucose. Taking it with food also blunts gastrointestinal upset. If deglycosylation by gut bacteria is required, a fibre-rich diet that supports a diverse microbiome may be a precondition for response.

  • Exercise: Potentiating and mechanistically aligned. Exercise itself activates AMPK, and the crossover trial (Nayyar et al., 2023) found supplementation raised post-exercise AMPK activation and muscle oxygen flux above training alone, improving 20 km time-trial performance. No blunting of strength or hypertrophy adaptation has been reported or tested. Dosing before training matches the mechanism.

  • Stress management: Direct but modest. Eight weeks of extract lowered trait anxiety by 16.8% more than placebo in chronically stressed adults (Choi et al., 2019), yet cortisol, adrenocorticotropic hormone and heart-rate variability were all unchanged, so it is not acting on the stress-hormone axis. It complements rather than substitutes for behavioural stress work.

Monitoring Protocol & Defining Success

Baseline testing before the first dose serves two purposes: it establishes whether jiaogulan has anything to act on, and it captures the two safety values most worth watching. The baseline panel comprises fasting glucose, HbA1c, insulin, a full lipid panel and liver enzymes, plus a complete blood count for the platelet count. Seated blood pressure and, where available, a body-composition scan complete it.

Ongoing monitoring follows a simple cadence: the complete blood count is repeated at 4 weeks to catch any early platelet fall, the full panel at 12 weeks to judge whether the intervention is working, and testing continues every 6 months for as long as use does. Daily self-checked fasting glucose through the first 4 weeks applies to anyone taking glucose-lowering medication.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Fasting glucose 75–86 mg/dL (4.2–4.8 mmol/L) Primary target of the best-supported effect Conventional range runs to 99 mg/dL; requires a 10–12 hour fast; paired with fasting insulin
HbA1c 4.8–5.3% Confirms a sustained rather than a single-day glucose change HbA1c is glycated haemoglobin, an average of blood sugar over roughly three months; conventional cut-off is under 5.7%; no fasting needed
Fasting insulin 2–5 µIU/mL Distinguishes true insulin sensitisation from simple glucose lowering Conventional labs often report up to 25 µIU/mL as normal; must be drawn fasting with the glucose sample
HOMA-IR Below 1.0 Single number summarising insulin resistance, the outcome improved in the tea trials HOMA-IR is the homeostatic model assessment of insulin resistance, calculated from fasting glucose and insulin; conventional threshold is 2.5
Triglycerides Below 80 mg/dL (0.9 mmol/L) The lipid fraction jiaogulan moves most reliably Conventional cut-off is 150 mg/dL; strongly affected by alcohol in the preceding 48 hours and by fasting state
HDL cholesterol Above 60 mg/dL (men), above 70 mg/dL (women) The second lipid fraction with meta-analytic support HDL is high-density lipoprotein; conventional floor is 40 mg/dL for men and 50 for women; runs with the same fasting draw
ALT 10–20 U/L (men), 8–17 U/L (women) Fatty liver marker that fell in two trials ALT is alanine aminotransferase, a liver enzyme; conventional upper limits of 40–55 U/L are far too permissive for functional interpretation
Platelet count 200–350 × 10⁹/L The one documented serious adverse signal Conventional range is 150–450 × 10⁹/L; comes as part of a complete blood count; a fall within the conventional range still warrants attention
Visceral fat mass No established target for jiaogulan; track change from the individual’s own baseline The body-composition endpoint that moved in trials Requires a DXA (dual-energy X-ray absorptiometry) scan; the trial effect was 109 g lost in men over 16 weeks, so measurement error matters — comparability depends on the same machine
Seated blood pressure Below 120/80 mmHg Detects the theoretical additive vasodilation Measured after 5 minutes seated; a standing reading is added at 2 and 4 weeks when blood-pressure medication is in use

Qualitative markers worth tracking alongside the labs:

  • Perceived exertion during a familiar aerobic session, which improved measurably in the fatigue trial (Ahn et al., 2023)
  • Endurance session performance at a fixed effort, such as a repeated timed route
  • Daytime energy stability, particularly the mid-afternoon dip that tracks glucose handling
  • Anxiety and stress reactivity, ideally with a repeated written self-rating rather than recall
  • Sleep onset and continuity, given the insomnia reports
  • Appetite and waist fit, which change before scale weight does
  • Unusual bruising, gum bleeding or petechiae (pinpoint red spots caused by bleeding under the skin), which would prompt an immediate platelet count

Emerging Research

  • Metabolic syndrome trial (NCT05118698): A 150-participant study at First Affiliated Hospital of Xi’an Jiaotong University testing jiaogulan against weight, blood lipid and blood glucose change in metabolic syndrome. Status is listed as unknown, so results may never appear.

  • Jiaogulan-containing formula in liver cirrhosis (NCT07017426): A 432-participant randomised, double-blind, placebo-controlled multicentre study of Fuzheng Huayu tablets, which contain Gynostemma pentaphyllum, on recurrent decompensation in hepatitis B cirrhosis. The largest registered study touching the herb.

  • Terminated optic neuritis pilot (NCT02976766): Stopped after 10 of 28 planned randomisations and missed its retinal nerve fibre layer endpoint (Lu et al., 2026). A concrete example of how thin the neurological evidence is.

  • Microbiome dependence of response: Li et al., 2023 paired their lipid meta-analysis with mouse metagenomics showing altered gut flora and tryptophan metabolism. If confirmed in humans, response could become predictable from a stool test rather than a genotype.

  • Evidence that could weaken the case: Dai et al., 2022 graded most lipid findings very low certainty and found red yeast rice superior head-to-head. A properly blinded, adequately powered, non-manufacturer-funded trial could shrink the effect substantially.

  • The gap that matters most: No trial has measured cardiovascular events, liver histology, or mortality, and none has run beyond 24 weeks. Until an outcome trial exists, every claim here rests on surrogate markers.

Conclusion

Jiaogulan is a leaf tea and supplement whose active plant compounds resemble those of ginseng and appear to work through the cell’s energy-sensing switch. The clearest human finding is better blood sugar handling: pooled trial data show meaningful drops in fasting glucose and in the three-month blood sugar average, and two independent trials using plain leaf tea reproduced this. Lower triglycerides, higher protective cholesterol, modest fat loss and better endurance follow at a weaker level of evidence, and the liver, anxiety and hair findings rest on single unreplicated trials. The claims around cancer, brain protection and blood vessel function come from laboratory and animal work only.

On the risk side, mild digestive upset is common and reverses, one case of a severe drop in platelets has been reported and resolved on stopping, and the herb can add to the effect of diabetes medication. Long-term human safety beyond about six months is simply unstudied.

The evidence base has two structural weaknesses worth weighing. Much of the body-composition, fatigue and hair evidence was funded by the companies selling the ingredient, and one prominent publisher of favourable jiaogulan content also sells the product. Meanwhile no insurer or drug maker has any financial reason to fund an independent confirmatory trial. For someone with elevated blood sugar or blood fats, the metabolic signal is real, but the certainty behind it remains low.

Top - Benefits - Risks - Protocol